Linaclotide Solid State Form III Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current forms of Linaclotide lack optimal stability, solubility, and bioavailability, which are crucial for effective treatment of gastrointestinal disorders, necessitating the development of new solid state forms with improved properties.
Innovation Solution
The development of novel solid state form III of Linaclotide, characterized by specific X-ray powder diffraction patterns and solid-state NMR spectra, which is prepared through a solvent removal process involving ethanol and water, and can be used to create pharmaceutical compositions with enhanced chemical and thermal stability, and improved handling characteristics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If existing solid state forms of Linaclotide are used, then the basic therapeutic function is achieved, but chemical stability and shelf-life are insufficient
Solution Approach 1:
The patent applies parameter changes by discovering and utilizing different solid state forms (polymorphs, solvates, and salts) of Linaclotide, each with distinct physical and chemical properties. Specifically, Form III and its dihydrate solvate exhibit superior chemical stability and shelf-life compared to previously known forms, directly addressing the stability-duration contradiction through variation in solid state parameters.
2Reliability
If existing solid state forms of Linaclotide are used, then the drug can be administered, but bioavailability is not optimized
Solution Approach 1:
The patent utilizes parameter changes in the solid state form of Linaclotide to simultaneously improve both bioavailability and solubility. The discovery of specific polymorphic forms and solvates (particularly Form III and its dihydrate) provides optimized dissolution profiles and enhanced bioavailability while maintaining adequate stability, resolving the contradiction between these two critical pharmacokinetic parameters.
3Ease of manufacture
If existing solid state forms of Linaclotide are used, then formulation is possible, but processing and handling characteristics are suboptimal
Solution Approach 1:
The patent applies parameter changes by identifying solid state forms with optimized physical properties for manufacturing and handling. Form III and its dihydrate solvate exhibit improved flowability, compressibility, and overall processing characteristics compared to previous forms, directly addressing the contradiction between ease of manufacture and ease of operation in pharmaceutical processing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new solid state form III of Linaclotide exhibits improved chemical purity, stability, and bioavailability, offering better processing and handling properties, and extended shelf-life, making it suitable for effective treatment of gastrointestinal disorders.
Implementation Method 1
The Linaclotide form III, and the pharmaceutical compositions and/or formulations of the present invention can be used as medicaments
Implementation Method 2
characterized by data selected from one or more of the following: an X-ray powder diffraction pattern having peaks at 5.1, 7.7, 10.3, 14.8 and 22.0 degrees two theta
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Solid state forms of Linaclotide, processes for their preparation, compositions comprising them and medical uses thereof are provided. The solid state forms of Linaclotide are useful in the preparation of other solid state forms of Linaclotide, particularly the amorphous form.